Volume 29, Number 7—July 2023
Research
Long-Term Epidemiology and Evolution of Swine Influenza Viruses, Vietnam
Table 2
HA lineage | Reference antigen | No. (%) seropositive† |
||
---|---|---|---|---|
2013–2015, n = 320 | 2016–2019, n = 440 | Overall, n = 760 | ||
2009 pandemic H1N1 |
A/California/04/2009 (H1N1) |
57 (17.8) |
61 (13.9) |
118 (15.5)† |
Pre-2009 human seasonal H1-δ–like |
A/swine/Hanoi/11-260/2019 (H1N2) |
43 (13.4) |
89 (20.2) |
132 (17.4)† |
Pre-2009 human seasonal H1-δ1a |
A/swine/Hanoi/12-276/2019 (H1N2) |
0 |
36 (8.2) |
36 (4.7) |
H1-TR |
A/swine/Hanoi/7-305/2016 (H1N2) |
10 (3.1) |
8 (1.8) |
18 (2.4) |
2004/05 human H3N2-origin |
A/swine/Hanoi/10-984/2018 (H3N2) |
49 (15.3) |
70 (15.9) |
119 (15.7) |
Total positive | 126 (39.4) | 183 (41.6) | 309 (40.7) |
*Seropositivity defined as hemagglutination inhibition assay titer ≥40. HA, hemagglutinin; TR, triple reassortant. †A total of 30 serum samples were positive for both A/California/04/2009 (H1N1) and A/swine/Hanoi/11–260/2019 (H1N2). Because cross reactivity between these viruses is low, this result likely indicates sequential infections.
1These senior authors contributed equally to this article.
Page created: May 10, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.